Proteomics International Laboratories has secured a worldwide licence to commercialise QIMR Berghofer Medical Research Institute’s oesophageal cancer biomarkers.
The new collaboration is intended to improve the detection of oesophageal adenocarcinoma, which is the most common form of oesophageal cancer.
Under the terms of the deal, QIMR Berghofer’s intellectual property in the biomarkers will be licensed exclusively to Proteomics, which will use it to develop and commercialise a simple blood test for oesophageal adenocarcinoma.
